Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Price Target at $42.33

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $42.3333.

A number of brokerages recently commented on COLL. Needham & Company LLC restated a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Wednesday, October 8th. HC Wainwright upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price objective for the company in a research report on Monday, August 11th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 23rd. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th.

Insider Activity

In other news, EVP Thomas B. Smith sold 17,478 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the completion of the sale, the executive vice president directly owned 70,264 shares in the company, valued at approximately $2,699,542.88. This trade represents a 19.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Scott Dreyer sold 16,389 shares of Collegium Pharmaceutical stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $38.21, for a total transaction of $626,223.69. Following the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $3,959,052.73. The trade was a 13.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 55,792 shares of company stock worth $2,084,207 in the last three months. 2.51% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. lifted its position in shares of Collegium Pharmaceutical by 1.4% during the 2nd quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company’s stock valued at $863,000 after acquiring an additional 409 shares during the period. SummerHaven Investment Management LLC lifted its position in shares of Collegium Pharmaceutical by 2.1% during the 2nd quarter. SummerHaven Investment Management LLC now owns 24,868 shares of the specialty pharmaceutical company’s stock valued at $735,000 after acquiring an additional 514 shares during the period. Legal & General Group Plc lifted its position in shares of Collegium Pharmaceutical by 0.6% during the 2nd quarter. Legal & General Group Plc now owns 89,829 shares of the specialty pharmaceutical company’s stock valued at $2,656,000 after acquiring an additional 531 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Collegium Pharmaceutical by 6.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,252 shares of the specialty pharmaceutical company’s stock valued at $244,000 after acquiring an additional 534 shares during the period. Finally, Sei Investments Co. raised its position in shares of Collegium Pharmaceutical by 5.5% during the 2nd quarter. Sei Investments Co. now owns 11,436 shares of the specialty pharmaceutical company’s stock worth $338,000 after purchasing an additional 600 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $36.00 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $39.95. The business’s 50-day moving average price is $35.76 and its 200 day moving average price is $32.41. The firm has a market cap of $1.13 billion, a P/E ratio of 34.62 and a beta of 0.65.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%.The firm had revenue of $135.55 million for the quarter. On average, equities research analysts expect that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical announced that its Board of Directors has approved a share buyback plan on Monday, July 7th that permits the company to repurchase $150.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to reacquire up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.